Apellis Pharmaceuticals (APLS) investor relations material

Strategic focus and growth outlook

• Emphasis on complement pathway therapies, with SYFOVRE and EMPAVELI as key growth drivers for both near and long term.

• 2025 described as a foundational year, building revenue streams and pipeline for future expansion.

• 2026 priorities include maximizing SYFOVRE in geographic atrophy, expanding EMPAVELI in rare nephrology, and advancing next-generation therapies.

• Company remains self-funded, prioritizing commercial execution, pipeline development, and capital deployment to drive revenue and profitability.

• Global expansion strategies under consideration, including potential European market re-entry.

SYFOVRE: Market leadership and innovation

• Maintains ~60% market share in geographic atrophy, with $587M in 2025 U.S. net product revenue and stable new patient share at 50-55%.

• Five-year GALE data demonstrated durable efficacy and safety, supporting long-term use.

• Prefilled syringe program and regulatory submission planned (2024–1H 2026) to enhance adoption and streamline retina practice workflow.

• AI-driven functional OCT imaging and augmented reality tools enhance demonstration of patient benefit and early GA identification.

• Market growth supported by improved practice flow and anticipated expansion into early-stage patient segments.

EMPAVELI: Rare disease launch and pipeline expansion

• EMPAVELI approved for C3G and IC-MPGN, with >5% market penetration after first full quarter and strong early launch.

• Generated $102M in FY 2025 U.S. net product revenue and demonstrated robust efficacy and safety across indications.

• Launch success attributed to strong efficacy, safety profile, positive payer reception, and start form performance outpacing other rare nephrology launches.

• Ongoing pivotal trials in FSGS and DGF target significant unmet needs in rare kidney diseases.

• Pediatric and transplant populations show higher urgency and uptake.